Last reviewed · How we verify
KLS-2031
At a glance
| Generic name | KLS-2031 |
|---|---|
| Sponsor | Kolon Life Science |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy (PHASE1, PHASE2)
- A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLS-2031 CI brief — competitive landscape report
- KLS-2031 updates RSS · CI watch RSS
- Kolon Life Science portfolio CI